BioWorld

Dec. 22, 2005

Genzyme Acquires Avigen's AAV Assets For $12M, More

Eight months after Avigen Inc. decided to stop funding its adeno-associated virus technology, it found a buyer in Genzyme Corp. (BioWorld Today) Read More

Oscient, FDA Agree On Phase III Plan For Antibiotic Ramoplanin

As One Large-Scale Project Begins, Another Called For

Acologix's Series C: $25M For AC-820 Phase III Trial

Other News to Note

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026